Literature DB >> 9814675

The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment.

R A Asherson1.   

Abstract

A review of 50 patients who manifest features of the catastrophic antiphospholipid syndrome (CAPS) is presented. The clinical features comprise mainly organ involvement as opposed to large-vessel venous or arterial occlusions as is seen in patients with 'simple' antiphospholipid syndrome (APS), which makes the pathogenesis of this unusually rare complication perhaps somewhat different from that of patients with the APS. The mortality of the condition is 50%, most patients dying as a result of a combination of cardiac and respiratory failure. Fifteen patients (28%) suffered from disseminated intravascular coagulation (DIC) as well, which may have contributed to the multiorgan thrombotic microangiopathy characteristic of the CAPS. Although most patients were treated with high-dose i.v. steroids, heparin, cyclophosphamide and other modalities of therapy (such as i.v. globulin), plasmapheresis (advocated for TTP, a similar microangiopathic condition) seemed to offer some benefit (68% recovery). The systemic inflammatory response syndrome (SIRS) was responsible for some of the clinical manifestations such as adult respiratory distress syndrome (ARDS) seen in 15 patients. Pathogenesis of the CAPS seems dependent on a 'two-hit' or even 'three-hit' hypothesis in patients already suffering from a hypercoagulable state. Precipitating factors include infections, trauma (surgical), drug administration and warfarin withdrawal. A recent view that the multiple thrombotic lesions themselves may contribute to further thrombosis ('thrombotic storm') is also discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814675     DOI: 10.1177/096120339800700214

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  14 in total

1.  Catastrophic antiphospholipid antibody syndrome following initiation of hemodialysis.

Authors:  Hideki Yotsueda; Kazuhiko Tsuruya; Masanori Tokumoto; Hideki Hirakata; Mitsuo Iida
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

Review 2.  Treatment of catastrophic antiphospholipid syndrome.

Authors:  Nayef M Kazzaz; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

3.  Catastrophic antiphospholipid syndrome masquerading as ischaemic colitis.

Authors:  Jan Steffen Jürgensen; Ralf Kettritz; Wolfgang Schneider; Herbert Koop; Thorsten Sven Hildebrand; Ulrich Frei; Kai-Uwe Eckardt
Journal:  Rheumatol Int       Date:  2003-03-29       Impact factor: 2.631

Review 4.  Neurologic manifestations of the antiphospholipid syndrome.

Authors:  D Tanne; S Hassin-Baer
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 5.  Diagnosis and management of the antiphospholipid syndrome.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Blood Rev       Date:  2017-07-30       Impact factor: 8.250

Review 6.  The roll of Toll-like receptors in the antiphospholipid syndrome.

Authors:  Julia Hurst; Mareike Lorenz; Nadine Prinz; Philipp von Landenberg
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

Review 7.  Lupus vasculitis: differential diagnosis with antiphospholipid syndrome.

Authors:  Theo Dov Golan
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 8.  The antiphospholipid syndrome: from pathophysiology to treatment.

Authors:  Simone Negrini; Fabrizio Pappalardo; Giuseppe Murdaca; Francesco Indiveri; Francesco Puppo
Journal:  Clin Exp Med       Date:  2016-06-22       Impact factor: 3.984

Review 9.  Antiphospholipid syndrome: an overview.

Authors:  John G Hanly
Journal:  CMAJ       Date:  2003-06-24       Impact factor: 8.262

10.  Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus.

Authors:  Selcan Demir; Jessica Li; Laurence S Magder; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.